AVAX Technologies, Inc. (AVXT)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0001 - Volume
2,410 - Avg. Volume
0 - Market Cap (intraday)
6.417M - Beta (5Y Monthly) -21.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
www.avax-tech.comRelated News
Performance Overview: AVXT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVXT
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
9.71
Enterprise Value/EBITDA
-0.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-457.32%
Return on Equity (ttm)
--
Revenue (ttm)
142.5k
Net Income Avi to Common (ttm)
-11.99M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
86.4k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.41M
Company Insights: AVXT
AVXT does not have Company Insights